These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27576612)

  • 1. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
    Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
    Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
    Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
    Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.
    Akahane K; Murakami Y; Kagami K; Abe M; Harama D; Shinohara T; Watanabe A; Goi K; Nishi R; Yamauchi T; Kimura S; Takita J; Look AT; Minegishi M; Sugita K; Inukai T
    Hematol Oncol; 2019 Oct; 37(4):516-519. PubMed ID: 31335977
    [No Abstract]   [Full Text] [Related]  

  • 4. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
    Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
    Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
    Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
    Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
    Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
    Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nelarabine in the treatment of refractory T-cell malignant diseases.
    Kline J; Larson RA
    Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
    Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
    Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nelarabine: efficacy in the treatment of clinical malignancies.
    Roecker AM; Allison JC; Kisor DF
    Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
    Miller LH; Maxa KL; Winter SS; Gossai NP
    Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Kadia TM; Gandhi V
    Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
    Kisor DF
    Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.